Summary: UnitedHealthcare modified its Molecular Pathology/Molecular Diagnostics/Genetic Testing coverage policy for Medicare Advantage plans, with an effective date of June 2, 2026. Here's what billing teams need to do before that date.
UnitedHealthcare — the full official name of the payer operating these Medicare Advantage plans — updated this policy governing genetic testing and molecular diagnostics reimbursement. The policy does not publish a specific policy code in UHC's system. Specific CPT and HCPCS codes are not listed in the available policy data for this update, which we address directly below. If your practice or lab bills for molecular pathology, pharmacogenomics, hereditary cancer panels, or any category of genetic testing under a UHC Medicare Advantage plan, this change is worth your attention before June 2, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare (Medicare Advantage) |
| Policy | Molecular Pathology/Molecular Diagnostics/Genetic Testing – Medicare Advantage Medical Policy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-06-02 |
| Impact Level | High |
| Specialties Affected | Pathology, Oncology, Genetics, OB/GYN, Internal Medicine, Neurology, Cardiology, Clinical Lab |
| Key Action | Pull your UHC Medicare Advantage genetic testing claims from the last 12 months and audit them against the updated coverage criteria before June 2, 2026. |
UnitedHealthcare Genetic Testing Coverage Criteria and Medical Necessity Requirements 2026
This is one of the most financially exposed policy categories in Medicare Advantage billing. Genetic testing and molecular diagnostics generate high-dollar claims, and UHC's coverage policy in this space has historically been strict on medical necessity.
The policy data available for this specific modification does not include a full text summary of what changed between the prior version and the June 2, 2026 update. That's a problem — and it's not unusual with UHC Medicare Advantage policy modifications. The published update may reflect revised medical necessity criteria, changes to prior authorization requirements, updates to which test categories UHC considers experimental or investigational, or adjustments to documentation standards.
What we know from UHC's general approach to this coverage policy category: UHC Medicare Advantage applies a medical necessity framework to genetic testing that is more restrictive than original Medicare in several respects. Tests must typically be ordered by a treating physician, tied to a specific clinical indication, and supported by documentation in the medical record before the test is ordered — not just after results come back.
Prior authorization is a live issue for genetic testing under UHC Medicare Advantage. Many molecular pathology codes — particularly multi-gene panels and whole exome or genome sequencing — require prior auth before the test is performed. Running the test without prior authorization approval and billing afterward is one of the leading causes of claim denial in this category. If your lab or ordering providers aren't confirming prior auth requirements before drawing the specimen, this policy modification is a signal to fix that workflow now.
Medical necessity documentation for genetic testing needs to be specific. A vague clinical note saying "family history of cancer" won't hold up. UHC expects documentation of the specific clinical scenario, the differential diagnosis the test is meant to resolve, and why the result will change patient management. That standard hasn't softened under recent policy versions, and there's no indication it will here.
UnitedHealthcare Genetic Testing Exclusions and Non-Covered Indications
UHC's Medicare Advantage genetic testing coverage policy has consistently maintained a category of tests it considers experimental, investigational, or unproven. This matters directly to your claim denial rate.
Whole genome sequencing for non-oncologic indications has historically fallen into the not-covered category under Medicare Advantage. So has direct-to-consumer genetic testing billed through a clinical pathway. Predictive genetic testing without a documented clinical indication tied to current symptoms or active treatment decisions also tends to land in the excluded category.
Multi-gene hereditary cancer panels occupy a gray zone. UHC covers certain panels — BRCA1/2 testing for qualifying patients is the clearest example — but broader panels that include genes with limited clinical actionability have faced coverage denials. If your oncology or genetics billing team orders 80+ gene panels and bills UHC Medicare Advantage, audit those claims now.
Pharmacogenomic testing is another area where UHC's coverage policy has been inconsistent. Some drug-gene interaction tests are covered when tied to a specific prescribing decision. Others are not covered when ordered as a broad panel without a clear clinical trigger. Knowing which tests UHC covers for which indications before you bill is the only way to protect reimbursement in this category.
Since the specific changes in this June 2, 2026 modification aren't detailed in the available data, talk to your compliance officer before assuming your current billing approach still holds. A policy modification to this document could have tightened criteria in any of these areas.
Coverage Indications at a Glance
Because the specific policy text for this modification is not available in the published data, this table reflects UHC Medicare Advantage's general position on genetic testing categories based on the policy's historical framework. Treat this as a starting checklist, not a substitute for the full policy document.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| BRCA1/2 testing for hereditary breast/ovarian cancer risk | Generally Covered | Not specified in this update | Medical necessity and clinical criteria must be met; prior auth may apply |
| Hereditary colorectal cancer panels (Lynch syndrome) | Generally Covered | Not specified in this update | Documentation of family history and clinical criteria required |
| Tumor profiling for active cancer treatment decisions | Conditionally Covered | Not specified in this update | Coverage varies by test and cancer type; prior auth commonly required |
| Broad multi-gene hereditary cancer panels | Coverage Varies | Not specified in this update | Panels beyond established clinical utility face higher denial risk |
| Pharmacogenomic testing | Coverage Varies | Not specified in this update | Covered when tied to a specific prescribing decision; broad panels often not covered |
| Whole exome/genome sequencing (non-oncologic) | Generally Not Covered | Not specified in this update | Considered experimental for most non-cancer indications under Medicare Advantage |
| Carrier screening in low-risk populations | Generally Not Covered | Not specified in this update | Not a covered Medicare Advantage benefit in most UHC policies |
| Direct-to-consumer tests billed through clinical pathway | Not Covered | Not specified in this update | Excluded regardless of clinical framing |
UnitedHealthcare Genetic Testing Billing Guidelines and Action Items 2026
The June 2, 2026 effective date gives you a window to act. Use it.
| # | Action Item |
|---|---|
| 1 | Pull your UHC Medicare Advantage genetic testing claims from January 2025 through today. Sort by claim denial reason. If you're seeing denials for lack of medical necessity or missing prior authorization, those are the exact risk areas this policy modification may have sharpened. Fix the workflow, not just the claims. |
| 2 | Get the full updated policy text directly from UHC before June 2, 2026. The available data for this modification doesn't include the full policy language. Go to UHC's provider portal or call your UHC provider relations rep and request the updated policy document. You need the actual criteria — not a summary — before the effective date. |
| 3 | Audit your prior authorization workflows for molecular pathology billing. For every molecular diagnostic and genetic test your practice or lab orders under UHC Medicare Advantage, confirm whether prior auth is required. Build a reference list. If your billing team discovers prior auth gaps, fix the intake process before June 2, 2026 — not after a denial. |
| 4 | Review medical necessity documentation standards with your ordering providers. The note needs to show the specific clinical indication, why this test will change clinical management, and what decision depends on the result. Brief your providers on this before the effective date. One education session with your medical director and top ordering providers is worth dozens of reconsideration letters. |
| 5 | Flag any multi-gene panel orders for secondary review. Panels with broad gene counts face the most scrutiny under UHC Medicare Advantage. Add a checkpoint in your lab order workflow so someone reviews the panel against UHC's covered indications before the specimen is processed and the bill is generated. |
| 6 | Check for billing guidelines updates from UHC's clinical policy bulletins. UHC often publishes supporting documents alongside policy modifications. These companion documents sometimes include more specific coding guidance, diagnosis code pairings, and documentation checklists. They don't always make headlines but they change what gets paid. |
| 7 | If your practice handles high volume in this category, loop in your billing consultant or compliance officer now. Genetic testing and molecular diagnostics are audit targets. A policy modification to this coverage policy, even a modest one, signals that UHC has reviewed this area recently. That's worth treating seriously. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Molecular Pathology/Genetic Testing Under This Policy
The available policy data for this UnitedHealthcare Medicare Advantage modification does not list specific CPT, HCPCS, or ICD-10 codes. This is an important gap — and worth flagging directly.
This policy covers one of the broadest and most code-dense categories in the CPT code set. Molecular pathology codes in the 81100–81599 range, proprietary lab analyses (PLA) codes, and HCPCS codes for genetic testing kits and specimen handling all potentially fall within scope. But without the actual policy text specifying which codes are subject to the updated criteria, we can't responsibly publish a code table here.
What to Do Instead
Get the code list from UHC directly. When you request the updated policy document from UHC's provider portal or provider relations team, specifically ask for the associated code list or policy attachment. These documents often include the full CPT and HCPCS code inventory the policy applies to.
Cross-reference against your charge master. Once you have UHC's code list, compare it to your current charge capture for UHC Medicare Advantage payers. Any code on both lists needs a documentation and prior auth review.
Do not assume the prior version's code list still applies. Policy modifications sometimes add or remove codes. A code that was covered under prior criteria may now face additional documentation requirements — or vice versa.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.